Novartis AG (NVSEF)
OTCMKTS
· Delayed Price · Currency is USD
117.60
+2.27 (1.97%)
Jun 6, 2025, 9:54 AM EDT
Novartis AG Revenue
Novartis AG had revenue of $13.62B in the quarter ending March 31, 2025, with 12.38% growth. This brings the company's revenue in the last twelve months to $53.22B, up 11.50% year-over-year. In the year 2024, Novartis AG had annual revenue of $51.72B with 10.85% growth.
Revenue (ttm)
53.22B
Revenue Growth
+11.50%
P/S Ratio
4.34
Revenue / Employee
701.37K
Employees
75,883
Market Cap
230.96B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
| Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
| Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
| Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
| Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.70M |
Novartis AG News
- 4 days ago - Bristol Myers Inks $11 Billion Licensing Pact With BioNTech For Bispecific Cancer Drug - Benzinga
- 4 days ago - Novartis' Pluvicto shown to slow prostate cancer in earlier setting - Reuters
- 4 days ago - Novartis's Cancer Treatment Pluvicto Shows Positive Results in Trial - WSJ
- 4 days ago - Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer - GlobeNewsWire
- 8 days ago - Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019 - Benzinga
- 10 days ago - Novartis announces commencement of tender offer to acquire Regulus Therapeutics - GlobeNewsWire
- 17 days ago - If I Could Only Buy 2 Dividend Stocks Right Now (May 2025 Edition) - Seeking Alpha
- 22 days ago - New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline - GlobeNewsWire